Video

Dr. Saint Fleur-Lominy on Remaining Challenges in Myelofibrosis

Shella Saint Fleur-Lominy, MD, PhD, discusses remaining challenges in myelofibrosis.

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor, Department of Medicine, at NYU Langone Health’s Perlmutter Cancer Center, discusses remaining challenges in myelofibrosis.

Typically, patients with myelofibrosis are older and have existing comorbidities, says Saint Fleur-Lominy. Additionally, treatment options for these patients are associated with significant toxicities, explains Saint Fleur-Lominy.

Identifying better targets and more selective inhibitors may make treatment more tolerable for patients, says Saint Fleur-Lominy.

It is important to develop novel agents as the number of patients who are eligible for curative-intent hematopoietic stem cell transplantation is low, concludes Saint Fleur-Lominy.

Related Videos
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Andrew Davis, MD
Noa Biran, MD